Thromboembolic complications in inflammatory bowel disease

Area of Science:

• Gastroenterology
• Hematology
• Vascular Medicine

Background:

• Inflammatory bowel disease (IBD) patients exhibit a 1.5-3.5 times greater risk of thromboembolism compared to the general population.
• This risk escalates significantly during active disease flares.
• Thromboembolic events are a major, often underestimated, cause of morbidity and mortality in IBD.

Purpose of the Study:

• To highlight the increased risk of arterial and venous thromboembolism in IBD patients.
• To emphasize the high morbidity and mortality associated with these events.
• To underscore the need for standardized thromboembolism prophylaxis guidelines in IBD management.

Main Methods:

• Review of existing literature on thromboembolism in IBD.
• Analysis of risk factors, including acquired vs. congenital alterations.
• Comparison of thromboembolic event rates and characteristics in IBD versus non-IBD populations.

Main Results:

• IBD patients experience both arterial (e.g., stroke, mesenteric ischemia) and venous (e.g., DVT, PE) thromboembolisms at higher rates.
• Thromboembolism occurs in younger IBD patients and has a high recurrence rate.
• Acquired risk factors are predominant in the etiopathogenesis of thromboembolism in IBD.

Conclusions:

• Thromboembolism is a critical extraintestinal complication in IBD with substantial mortality (up to 25% per episode).
• Standardized guidelines for thromboembolism prophylaxis in IBD are critically needed.
• Adherence to clinical guidelines can prevent significant morbidity and mortality.